Pharmaron (康龙化成)
Beijing-founded full-service CRO/CDMO — laboratory chemistry and biosciences, CMC and clinical services across China, the UK and the US.
1. Core Product / Service
Pharmaron (康龙化成), founded 2004 in Beijing, is an integrated drug R&D services company. Its core is laboratory services (discovery chemistry and biosciences), followed by CMC (small-molecule CDMO), clinical research services, and a smaller biologics/cell-and-gene-therapy unit. It operates 21 R&D and production sites across China, the UK and the US and serves 3,000+ clients [1].
2. Target Users & Pain Points
Global pharma and biotech outsourcing discovery-to-IND laboratory work, plus small-molecule CMC manufacturing — the same "variable cost instead of fixed lab" logic as wuxi-apptec, with a smaller but full-stack footprint.
3. Competitive Landscape
| Player | Type | Vs. Pharmaron |
|---|---|---|
| wuxi-apptec | Full-stack CRDMO | Larger, chemistry-led, TIDES at scale |
| Pharmaron | Integrated CRO/CDMO | Full-service, strong lab-chemistry base |
| asymchem | CDMO (small molecule + peptides) | Manufacturing-focused, peptide push |
| genscript | Gene synthesis + biologics CDMO | Upstream DNA, not classic lab CRO |
| Charles River / Labcorp | Western CRO | US-listed preclinical incumbents |
4. Unique Observations
- Lab services are the business. Discovery chemistry and biosciences brought in RMB 7.05B of the RMB 12.28B FY2024 revenue (~57%) — Pharmaron is first a laboratory CRO, with manufacturing as the second leg [1].
- CMC is the fastest-growing segment. Small-molecule CDMO grew +10.2% in FY2024, ahead of lab services (+5.8%) and clinical (+5.1%), while biologics & CGT was the only segment that shrank (−4.1%) [1].
- Three-country footprint. Its 21 sites span China, the UK and the US, giving it Western capacity that purely domestic peers lack [1].
5. Financials / Funding
- FY2024 revenue: RMB 12.28B (+6.4% YoY); net profit attributable to shareholders RMB 1.79B (+12.0%) [1].
- Segment split FY2024: laboratory services RMB 7.05B (+5.8%); CMC (small-molecule CDMO) RMB 2.99B (+10.2%); clinical research RMB 1.83B (+5.1%); biologics & CGT RMB 0.41B (−4.1%) [1].
- Listings: SZSE ChiNext 300759.SZ (IPO Jan 28, 2019) and HKEX 3759.HK (Nov 28, 2019) [1].
- Employees ~21,370; 3,000+ clients [1].
6. People & Relationships
- Founder, Chairman & CEO: Dr. Boliang Lou (楼柏良); co-founders Lou Xiaoqiang (COO/President) and Zheng Bei (EVP) [1].
- Peers / competitors: wuxi-apptec, asymchem, genscript, Charles River, Labcorp.
Sources
[1] Pharmaron 2024 annual results announcement, HKEX (stock code 3759), https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0326/2025032601437_c.pdf (2026-10-19).